Abstract:Engineering immune cells to target cancer is a rapidly advancing technology. The first commercial products, chimeric-antigen receptor (CAR) T cells, are now approved for hematologic malignancies. However, solid tumors pose a greater challenge for cellular therapy, in part because suitable cancer-specific antigens are more difficult to identify and surrounding healthy tissues are harder to avoid. In addition, impaired trafficking of immune cells to solid tumors, the harsh immune-inhibitory microenvironment, and variable antigen density and presentation help tumors evade immune cells targeting cancer-specific antigens. To overcome these obstacles, T cells are being engineered to express defined T-cell receptors (TCR). Given that TCRs target intracellular peptides expressed on tumor MHC molecules, this provides an expanded pool of potential targetable tumor-specific antigens relative to the cell-surface antigens that are targeted by CAR T cells. The affinity of TCR T cells can be tuned to allow for better tumor recognition, even with varying levels of antigen presentation on the tumor and surrounding healthy tissue. Further enhancements to TCR T cells include improved platforms that enable more robust cell expansion and persistence; coadministration of small molecules that enhance tumor recognition and immune activation; and coexpression of cytokine-producing moieties, activating coreceptors, or mediators that relieve checkpoint blockade. Early-phase clinical trials pose logistical challenges involving production, large-scale manufacturing, and more. The challenges and obstacles to successful TCR T-cell therapy, and ways to overcome these and improve anticancer activity and efficacy, are discussed herein.

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu

Genetically engineered T cells for cancer immunotherapy

TCR-engineered T cell therapy in solid tumors: State of the art and perspectives

Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects

Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges

Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy

TCR-T Immunotherapy: The Challenges and Solutions

Engineered T-cell Receptor T Cells for Cancer Immunotherapy

How does TCR-T cell therapy exhibit a superior anti-tumor efficacy

Emerging Strategies in TCR-Engineered T Cells

Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons

Engineered T Cell Receptor for Cancer Immunotherapy

Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application

TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals

Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment

T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance

Progress in T cell receptor-gene engineered T cell immunotherapy for solid tumors

TCR engineered T cells for solid tumor immunotherapy

TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges

T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome

Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells